Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02434744 · ClinicalTrials.gov registry record · Phase 2

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Response Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
121
Enrollment target
10
Study locations

NCT02434744 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by Response Pharmaceuticals. The registered enrollment target is 121 participants, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02434744, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by Response Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
121 participants
Enrollment target
10
Study locations

Study Summary

This study will compare the safety, tolerability and efficacy of the combination of KD026 and metformin compared to placebo and metformin on improving glycemic control in patients with type 2 diabetes mellitus.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Metformin
  • DRUG KD026

Study Locations (10)

California

  • Axis Clinical Trials - Los Angeles
  • National Research Institute - Los Angeles
  • Infosphere Clinical Research, Inc - West Hills

Florida

  • Clinical Research of South Florida - Coral Gables
  • Med Research of Florida, LLC - Miami

Alabama

  • Achieve Clinical Research, LLC - Birmingham

North Carolina

  • High Point Clinical Trials Center - High Point

South Carolina

  • Coastal Carolina Research Center - Mt. Pleasant

Texas

  • Clinical Trial Network - Houston

Virginia

  • Clinical Research Associates of Tidewater - Norfolk

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2015-04
Est. Completion 2016-03
Phase Phase 2

Sponsor

Response Pharmaceuticals

5 total trials

What the Registry Record Tells You About NCT02434744

The ClinicalTrials.gov registry entry for NCT02434744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (96% lower). The listed sponsor is Response Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02434744 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT02434744 about?

NCT02434744 is a clinical study titled "Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus". This study will compare the safety, tolerability and efficacy of the combination of KD026 and metformin compared to placebo and metformin on improving glycemic control in patients with type 2 diabetes mellitus.

What is the current status of trial NCT02434744?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2015-04. Estimated completion is 2016-03.

What conditions does trial NCT02434744 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT02434744?

The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), KD026 (DRUG).

Who is sponsoring clinical trial NCT02434744?

This trial is sponsored by Response Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02434744 being conducted?

This trial has 10 study locations across Alabama, California, Florida, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.